

FEATURE ARTICLE

[View Article Online](#)
[View Journal](#) | [View Issue](#)

The taming of oxygen: biocatalytic oxyfunctionalisations

Cite this: *Chem. Commun.*, 2014, 50, 13180

Dirk Holtmann,^a Marco W. Fraaije,^b Isabel W. C. E. Arends,^c Diederik J. Opperman^d and Frank Hollmann^{*c}

Received 24th December 2013,
Accepted 23rd May 2014

DOI: 10.1039/c3cc49747j

www.rsc.org/chemcomm

Introduction

Selective oxyfunctionalisation of non-activated hydrocarbons represents a contemporary issue of organic chemistry. The inertness of most C–H bonds requires powerful oxygen transfer agents.¹ High activity, however, is frequently accompanied by poor selectivity, which is in contrast to the demands of modern chemical synthesis.²

Nature provides us with a class of catalysts that comprises both features: activity and selectivity: Oxygenases catalyse the introduction of oxygen atoms from molecular oxygen or hydrogen peroxide

into (non-)activated C–H- and C=C-bonds and to heteroatoms. Often, these oxyfunctionalisation reactions occur highly selectively. Many oxygenases are selective for only one position in structurally complex molecules and they introduce the oxygen atoms with high stereocontrol. Furthermore, overoxidation, which is a frequent problem in chemical oxyfunctionalisation, is far less observed in enzymatic oxyfunctionalisations. This unique combination of activity and selectivity stems from the embedding of reactive oxygen transfer reagents such as highly oxidised iron–oxo complexes or organic peroxides in the cavity of an enzyme's active site. The well-defined and chiral environment not only positions the starting material precisely to the 'hot' oxygen atom transferred (accounting for selectivity) but also stabilises transition states thereby leading to, sometimes dramatic, rate accelerations as compared to the biomimetic analogues (Scheme 1).

Therefore, it is not very astonishing that the interest in biological oxyfunctionalisation chemistry has been steadily growing over the past decades. We are convinced that oxygenases,

^a DECHEMA Research Institute, Theodor-Heuss-Allee 25, 60486 Frankfurt am Main, Germany

^b Molecular Enzymology group, Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands

^c Department of Biotechnology, Delft University of Technology, Julianalaan 136, 2628 BL Delft, The Netherlands. E-mail: f.hollmann@tudelft.nl

^d Department of Biotechnology, University of the Free State, Bloemfontein 9300, South Africa



Dirk Holtmann

tions, the development and evaluation of electro-enzymatic processes as well as microbial electrosynthesis.




Marco W. Fraaije

biocatalysis, in particular the knowledge-based discovery, engineering and redesign of oxidative enzymes.



following the well-established hydrolases^{4–6} and the ever more popular dehydrogenases,^{5,7–10} will represent the next upcoming wave of biocatalysts used in chemical synthesis.¹¹

The aim of this perspective is to encourage organic chemists to consider oxygenases in their synthesis planning more often. For this, we will focus on the application of oxygenases for organic synthesis, giving an overview over the rich product spectrum available already today and discussing some recent preparative examples. In particular, we will cover the most-common oxygenases, *i.e.* flavin-dependent monooxygenases as well as heme-dependent monooxygenases and -peroxygenases. Also some perceived and real limitations *en route* to becoming truly practical catalysts, together with some promising solutions will be discussed. A detailed discussion of the catalytic mechanisms would be beyond the scope of this perspective; the interested reader is referred to some excellent reviews^{5,6,12–14} exhaustively covering our current mechanistic understanding.



Scheme 1 Oxygenases comprise highly reactive oxygenation agents such as (formal) Fe^{V} -oxyferryl-heme, or (hydro)peroxo-flavins embedded in the well-defined framework of an enzyme.³



Isabel W. C. E. Arends

Isabel Arends received her PhD in physical organic chemistry in 1993, from Leiden University, the Netherlands. Postdoctoral work followed with Keith Ingold at the NRC in Canada on selective liquid phase oxidations. She joined the group of Roger Sheldon at the Delft University of Technology in 1995. In 2007 she became full professor in biocatalysis at the same university. Her research focuses on redox biocatalysts, novel enzymes, and chemo/biocatalytic

methods for conversion of biomass. Prof. Arends is author of over 140 publications and 17 book chapters. She is co-author of the seminal monograph "Green Chemistry and Catalysis".



Diederik J. Opperman


Diederik J. Opperman obtained his PhD in biochemistry from the University of the Free State (South Africa) in 2008. He then joined the research group of Manfred T. Reetz at the Max-Planck-Institut für Kohlenforschung (Germany) as a postdoctoral co-worker in directed evolution. He is currently a senior lecturer and group leader at the University of the Free State (SA) with a research focus on the structure–function relationship of biocatalysts.



Frank Hollmann

Frank Hollmann studied Chemistry in Bonn, Germany. He received his PhD in Bioelectrocatalysis from the ETH in Zurich, Switzerland. After a postdoctoral stay at the MPI for Coal Research in Mülheim, Germany and some years with Evonik Goldschmidt he joined the Biocatalysis and Organic Chemistry group of TU Delft in 2008 as assistant professor. His research centres on the use of enzymes for organic synthesis. Particularly, he is interested in redox biocatalysis for stereospecific reduction and oxyfunctionalization chemistry using novel biocatalysts and alternative regeneration approaches.





Scheme 2 4a-(Hydro)peroxoflavin as the active species leading to the diverse reactions catalysed by flavin-dependent monooxygenases. (1) Epoxidation of C=C double bonds, (2) Baeyer–Villiger oxidation of (cyclic) ketones, (3) *ortho*- and *para*-hydroxylation of phenols, (4) heteroatom oxygenation, (5) oxidation of aldehydes, and (6) halogenation reactions.


flavin interacts with molecular oxygen to form an organic peroxide (4a-(hydro)peroxoflavin), which acts as the actual oxygen transfer agent (oxidative half reaction). The resulting 4a-hydroxyflavin eliminates water and thereby returns to the oxidized resting form (Scheme 3). Only very recently an alternative mechanism for oxygenation by a flavoprotein has been revealed.⁴¹ It was shown that the bacterial enzyme EncM, involved in the biosynthesis of the antibiotic enterocin, performs an

coenzyme-independent oxygen insertion *via* a reactive flavin N5-oxide. In this specific example, the reducing equivalents come from the substrate itself. It remains to be seen whether this is a rare example or whether there are more flavoproteins in nature that employ such a mechanism.

In principle, the chemical versatility of flavins should also allow for H₂O₂-driven oxyfunctionalisation reactions as frequently demonstrated with N5-alkylated flavins as ‘chemical catalysts’.²⁸ Recently, Fraaije and coworkers have demonstrated that flavoproteins can be engineered to act as peroxygenases by replacing the riboflavin cofactor in the riboflavin-binding protein with alkylated flavins. Overall the general feasibility of ‘flavoperoxygenases’ could be demonstrated (Scheme 4).⁴²


Organic chemists are probably most acquainted to the enzymatic Baeyer–Villiger oxidation mediated by so-called Baeyer–Villiger monooxygenases (BVMOs, Scheme 2, 2). Since some early contributions from the mid-20th century^{43–45} and the pioneering work by Trudgill and coworkers^{46,47} the scope of enzymatic Baeyer–Villiger reactions has been expanded significantly in the last two decades^{31,48–50} and a range of synthetically useful transformations have been reported (Table 1). Also, the first crystal structure of a BVMO⁵¹ has significantly contributed to the mechanistic understanding of BVMOs^{52,53} and enabled rational approaches to engineer tailored new BVMOs.^{54–64} Today, the enzymatic Baeyer–Villiger oxidation (in the form of whole cell biotransformation, *vide infra*) has reached the multi-kg scale^{65–68} and further scale-ups and industrial applications may be expected in the nearer future.

A special case of BVMO-catalysed Baeyer–Villiger oxidations is the oxygenation of aldehydes (Scheme 2, 5). In most cases, BVMOs convert aldehydes into the corresponding formyl esters (following the migration rules of the chemical Baeyer–Villiger oxidation). However, recently Bisagni and coworkers reported



Scheme 3 Simplified catalytic cycle of flavin-dependent monooxygenases. In the resting state of the enzyme the reduced nicotinamide cofactor (NAD(P)H) binds to the enzyme and transfers its hydride to the alloxazine moiety (1). In step (2) the reduced flavin reacts with molecular oxygen yielding the catalytically active (hydro)peroxoflavin, which, in step (3) performs the oxyfunctionalisation reaction. The resting state is regenerated after water extrusion (step (4)). Please note that for reasons of simplicity, protonation steps have been omitted from the scheme.





Scheme 4 Simplified scheme of a 'flavoperoxygenase' mechanism.

on a novel BVMO from *Dietzia* sp. preferentially catalysing acid formation of *e.g.* profene aldehydes.⁶⁹

Many of the aforementioned BVMOs are also capable of hetero-atom oxygenation (Scheme 2, 4). Enantiospecific sulfoxidation here clearly represents the reaction most frequently investigated.^{30,70–74} Next to the often high enantioselectivity of this reaction, also its high chemoselectivity is valued as the 'overoxidation product' *i.e.* the corresponding sulfone is usually not observed in enzymatic sulfoxidation reactions. Next to sulphur also other heteroatoms such as selenium,^{75–78} boron,^{77,79} or nitrogen⁴⁸ can be oxygenated using flavin-dependent monooxygenases. Recently, Codexis evolved cyclohexanone monooxygenase for the selective sulfoxidation to yield enantiopure (*S*)-pantoprazole (Scheme 5),^{74,80} thereby impressively demonstrating the potential of protein engineering to tailor a monooxygenase to meet the requirements of industrial-scale synthesis.

Also the regioselective hydroxylation of phenols (Scheme 2, 3) either in the *ortho*- or *para*-position represents a principally highly interesting reaction for organic synthesis as the repertoire of chemical aromatic hydroxylations (apart from Dakin-, Sandmeyer- and Baeyer–Villiger-type reactions as well as boronic acid oxidations) is rather limited. However, at present also the number of phenol hydroxylases is rather restricted as well.⁸¹ Nevertheless for example, 2-hydroxy biphenyl-3-monooxygenase (HbpA) has been used at up to kg-scale synthesis of catechols.^{82–89} But also phenol hydroxylase (PheA1),^{90–93} and the benzoate hydroxylases^{94–96} have been reported and might exhibit some synthetic potential.

Stereoselective epoxidation of C=C-double bonds (Scheme 2, 1) is an emerging field in flavoprotein-monooxygenase chemistry. Especially the so-called styrene monooxygenases are enjoying increased popularity. For example the styrene monooxygenase from *Pseudomonas* sp. VLB 120 has been investigated intensively by Schmid and coworkers.^{97–114} But also new styrene monooxygenases from other sources are constantly added to the portfolio.^{32,115–121}

Currently, the styrene monooxygenases available appear to have a clear preference for vinyl aromatic substrates even though also aliphatic alkenes have been reported as substrates.^{119,120} The more severe limitation of the present portfolio is that exclusively (*S*)-selective styrene monooxygenases are known. Hopefully, screening of natural diversity and/or protein engineering will close this gap in the nearer future.

An interesting cascade reaction producing enantiomerically pure (*S*)-styrene oxide from (renewable) phenylalanine in a cascade of amino lyase, decarboxylase and styrene monooxygenase was reported recently by Nielsen and coworkers (Scheme 6).¹²²

Also, flavoprotein monooxygenase-catalysed oxidative halogenation reactions (Scheme 2, 6) are worth mentioning here. In the stricter sense, these reactions are not oxyfunctionalisation reactions as a halogen is incorporated instead of an oxygen atom.^{123–133} According to our present knowledge, flavin-dependent halogenases primarily catalyse the oxidation of halogenides to hypohalous acids (HOCl, HOBr). These are guided by the protein backbone directly and exclusively to the substrate performing the electrophilic halogenation reaction. Even though, flavin-dependent halogenases seem to be limited to activated (aromatic) substrates, their exclusive regioselectivity should make them highly interesting tools not only for pharmaceutical applications. However, *en route* to preparative application their still comparably poor catalytic activity (k_{cat} being in the range of $<1 \text{ min}^{-1}$) needs to be addressed.

Very recently, an interesting cascade of tryptophan synthase and tryptophane-7-halogenase was reported giving access to a broad range of tryptophan derivates from simple indole starting materials (Scheme 7).¹³⁴

Finally, also a newly discovered long-chain alkane degrading flavoprotein monooxygenase (LadA) should be mentioned here.^{135,136} So far, this is the only flavin-dependent monooxygenase reported capable of hydroxylating non-activated hydrocarbons (being largely the domain of (non)-heme iron monooxygenases, *vide infra*). At present, only a few reports deal



Table 1 Representative examples of oxyfunctionalisation reactions mediated by flavin-dependent monooxygenases



















Substrate	Product	R	% Conv. (% yield)	Catalyst	ee (%)	Volumetric scale	Remarks	Ref.
(1) Epoxidation reactions								
		R ₁ = H, R ₂ = Me R ₁ = H, R ₂ = Me	(87) 95 (87)	SMO (rec in growing <i>E. coli</i>) SMO (crude cell extract)	>99 (<i>S</i>) 99.7 (<i>S</i>)	1 L 100 mL	[S] ₀ = 695 mM; t = 8 h [S] ₀ = 50 mM; t = 10 h; TON _(SMO) = 1844	100 114
		R ₁ = R ₂ = H, R ₃ = F, Cl, Br, Me	(90, 70, 31, 62)	SMO (rec in resting <i>E. coli</i>)	All > 99.9 (<i>S</i>) except 62.8 (<i>S</i>) for Me	1 mL	[S] ₀ = 200 mM; t = 24 h	119 and 120
		R ₁ = R ₃ = H, R ₂ = Cl	91 (73)	SMO (crude cell extract)	>99.9 (<i>S</i>)	100 mL	[S] ₀ = 50 mM; t = 10 h; TON _(SMO) = 2171	114
			(50)	SMO (rec in resting <i>E. coli</i>)	>99 epoxide (de = 98%)	20 mL	[S] ₀ = 4,5 mM; t = 2 h	137 and 138
		n = 1 n = 2	(48) (53)	SMO (rec in growing <i>E. coli</i>) SMO (rec in growing <i>E. coli</i>)	98 (<i>S</i>) 98.5 (<i>S</i>)	1 L 1 L	[S] ₀ > 150 mM; t = 19 h [S] ₀ > 150 mM; t = 45 h	112 112
		R ₁ = Et, Me	(40, 10)	CHMO (partially purified enzyme)	≥98 (<i>R</i>)	10 mL	[S] ₀ = 12 mM; t = 48 h	139
(2) Baeyer–Villiger oxidations								
								
			>99 (58)	CHMO (rec in growing <i>E. coli</i>)	99% (1 <i>R</i> ,5 <i>S</i>) 97 (1 <i>S</i> ,5 <i>R</i>)	50 L	900 g; [S] ₀ > 0.1 M; t = 20 h	65 and 66
						200 L	Fed-batch 4.5 g L ⁻¹ ; ([S] _{total} = 36 mM); t = 7 h	140
			>99	PAMO (partially purified enzyme)	>99 (<i>S</i>)	13 mL	[S] ₀ > 20 mM; t = 24 h; DKR	70
			47	HAPMO (partially purified enzyme)	>98% (pro- duct) E > 100	50 mL	KR; [S] ₀ = 5.4 mM	141
		R ₁ , R ₂ = Me, Et, nPr, iPr, nBu, allyl (independently)	50	CHMO (partially purified enzyme)	E > 200	1 mL	KR or desymmetrisation; [S] ₀ = 2 mM; t = 2 h	142



Table 1 (continued)

Substrate	Product	R	% Conv. (% yield)	Catalyst	ee (%)	Volumetric scale	Remarks	Ref.
(3) Phenol hydroxylation reactions								
		R = alkyl, aryl	>99	HbpA (partially purified enzyme)		10 mL	$[S]_0 = 160 \text{ mM}$; $t = 600 \text{ h}$ up to 160 mM	85 and 86
			>99	3HB6H (purified enzyme)		1 mL	$[S]_0 = 50 \text{ mM}$; $t = 8 \text{ h}$	92 and 143
			>99	PheA1 (rec in growing <i>E. coli</i>)		50 mL	$[S]_0 = 5 \text{ mM}$; $t = 10 \text{ h}$	90
(4) Heteroatom oxygenations								
			50%	PAMO (purified enzyme)	99 (unreacted enantiomer)	1 mL	KR; $[S]_0 = 10 \text{ mM}$; $t = 24 \text{ h}$	75 and 76
		decomposes spontaneously						
			49	PAMO (purified enzyme)	$E = 23$	0.5 mL	KR; $[S]_0 = 10 \text{ mM}$; $t = 24 \text{ h}$	79
			(45)	SMO (rec in resting <i>E. coli</i>)	54.5 (<i>S</i>)	1 mL	$[S]_0 = 200 \text{ mM}$; $t = 24 \text{ h}$	119 and 120

SMO: styrene monooxygenase; CHMO: cyclohexanone monooxygenase; BVMO: Baeyer–Villiger monooxygenase; PAMO: phenylacetone monooxygenase; HAPMO: 4-hydroxyacetophenone monooxygenase; HbpA: 2-hydroxy biphenyl-3-monooxygenase; PheA1: phenol hydroxylase; 3HB6H: 3-hydroxy benzoate-6-hydroxylase; (D)KR: (dynamic) kinetic resolution.

with this interesting enzyme and future will tell the preparative potential of LadA.


A representative selection of examples ranging from analytical proof-of-concept contributions to (near) industrial scale implementations is shown in Table 1.

Overall, flavin-dependent monooxygenases have great potential for organic synthesis. They enable highly selective introduction of molecular oxygen into organic compounds. Very often, a comparable chemical route is yet unknown. Unfortunately, at


present only a few of these promising catalysts are commercially available (e.g. some BVMOs).

Heme-iron-monooxygenases and -peroxygenases


Heme-iron-monooxygenases, also called P450- or CYP-monooxygenases, exhibit an even higher oxyfunctionalisation



Scheme 5 Cyclohexanone monooxygenase (CHMO)-mediated enantiospecific sulfoxidation for the synthesis of (S)-pantoprazole.



Scheme 6 Cascade from natural phenylalanine to (S)-styrene oxide entailing phenylalanine ammonia lyase (PAL), phenoloic acid decarboxylase (PADC) and styrene monooxygenase (SMO).

Scheme 7 Cascade for the synthesis of unnatural halogenated tryptophanes from simple indoles. TrpS: tryptophan synthase; Trp7-Hal: tryptophan-7-halogenase; Reg.-Sys.: FADH₂-regeneration system comprising a NADH:FAD oxidoreductase, NADH and an alcohol dehydrogenase.

potency than most of the flavoprotein monooxygenases discussed above. P450 monooxygenases can also abstract non-activated C–H bonds such as in alkanes. Obviously, this has inspired many research groups worldwide to explore the catalytic potential of this enzyme class (Scheme 8).^{20,21,144–147}


P450 monooxygenases comprise a somewhat more complicated mechanism than flavoprotein monooxygenases. Molecular oxygen is activated by coordination to a highly oxidized (formally Fe^{V}) iron species enabling electrophilic O-transfer. To achieve this, two additional reducing equivalents are necessary, which are delivered in two individual single electron transfer steps (Scheme 9).

Again, NAD(P)H serves as a source for the reducing equivalents needed. However, since NAD(P)H is an obligate hydride donor, it is not capable of interacting directly with the iron centre (being an obligate single electron acceptor). To overcome the mechanistic incompatibility of NAD(P)H and Fe^{3+} , nature uses *e.g.* NAD(P)H-ferredoxin oxidoreductases as relay systems. These enzymes contain flavins, which due to their mechanistic versatility, can accept a hydride from NAD(P)H and pass on the two electrons in two subsequent steps either to the monooxygenase directly or *via* electron transport proteins such as $\text{Fe}_{2}\text{S}_{2}$ ferredoxin (Scheme 10).


It is worth mentioning here that some P450 monooxygenases are capable of forming the catalytically active oxyferryl species from the resting state using hydrogen peroxide (Scheme 9). However, usually, their efficiency with H_2O_2 is relatively poor so that oxidative inactivation of the heme-prosthetic group (and the protein backbone) dominates. In contrast, the so-called peroxygenases utilise this hydrogen peroxide shunt pathway very efficiently enabling the H_2O_2 -driven P450-oxyfunctionalisation chemistry. In fact, it has been hypothesised that the P450 monooxygenases have evolved from H_2O_2 -dependent ancestors.¹⁵⁸

P450 monooxygenases have received tremendous attention due to their capability to hydroxylate non-activated C–H bonds. For example, the selective and mild hydroxylation of (cyclo)-alkanes represents a focus of research. The promise here lies in the high selectivity of the enzymatic hydroxylation avoiding undesired overoxidation of the (more reactive) reaction products as frequently encountered in (industrial) oxidation methods.¹⁵⁹ A very recent contribution by Gröger and coworkers nicely demonstrates the synthetic potential of biocatalytic oxyfunctionalisation (Scheme 11).^{160,161} By combining a P450-monooxygenase with an alcohol dehydrogenase, the authors achieved clean aerobic oxidation of cyclohexane to cyclohexanone with absolute selectivity.






Scheme 8 Compound I as the active species leading to the diverse reactions catalysed by P450-monoxygenases and peroxidases. (1) Hydroxylation of (non)activated C–H-bonds^{148–153} even of methane,^{154,155} (2) hydroxylation of aromatics,¹⁵⁶ (3) epoxidation of C=C-double bonds; (4) carbene transfer to C=C-double bonds (actually starting from the reduced Fe^{II} stage and not being an oxyfunctionalisation reaction).¹⁵⁷




Scheme 9 Simplified catalytic cycle of P450-monoxygenases. The catalytic cycle starts with binding of the substrate to the resting (Fe^{III}) state of the enzyme followed by single electron transfer (from NAD(P)H via the electron transport chain), O₂-binding and the second electron transfer. The resulting hydroperoxo iron is dehydrated after successive protonation resulting in a (formal) Fe^V-oxo species (compound I) performing the O-transfer reaction. The intermediate hydroperoxo iron can also be formed directly from the resting state by addition of H₂O₂ (hydrogen peroxide shunt).

The overall low yield of the reaction (<10%) is most probably attributed to the volatility of the reagents and the non-optimised reaction conditions. Nevertheless, the high selectivity of this

reaction convinces especially compared to chemical processes, where frequently by-products originating from overoxidation and ring-cleavage are observed.¹⁵⁹



Scheme 10 Transformation of a hydride transfer reagent (NAD(P)H) into two single electron transfer reagents (e.g. ferredoxin, Fd). NAD(P)H:ferredoxin oxidoreductase catalyse the oxidation of NAD(P)H (by hydride transfer to the enzyme-bound flavin cofactor, step (1)). The reduced flavin then successively delivers one electron each to two ferredoxins (Fd).



Scheme 11 Bi-enzymatic cascade for the selective aerobic oxidation of (cyclo)alkanes to the corresponding ketones using a sequence of P450 monooxygenase-catalysed hydroxylation (here P450BM3 from *Bacillus megaterium*) and ADH-catalysed further oxidation to the ketone.

Similar examples comprise the selective transformation of (cyclo)alkanols into the corresponding esters (e.g. cyclohexanol to ϵ -caprolactone).^{162,163}

Industrial interest in P450 monooxygenases today mainly stems from the pharmaceutical industry for the generation of drug metabolites and the production of active pharmaceutical ingredients (APIs) such as steroids.^{26,146,147,164,165}

But also selective oxyfunctionalisation of terpenes is of great interest.^{152,166–173}

A very elegant approach was reported by Keasling and coworkers who used an engineered *Saccharomyces cerevisiae* overexpressing a P450 monooxygenase to produce artemisinic acid (basically from sugar) (Scheme 12).^{174,175}


Often, P450 monooxygenase-catalysed reactions are still somewhat too slow and yield too low product titers (*vide infra*)²⁶ to meet the economic requirements for bulk chemicals.¹⁷⁶ Nevertheless, oxyfunctionalisation of fatty acids to yield α,ω -dicarboxylic acids (as polymer building blocks) has been demonstrated at appreciable product titres of more than 100 g L⁻¹ (ref. 177–180) pointing towards large-scale applicability of these biocatalysts.

For a long time, methane hydroxylation was believed to be limited to non-heme iron monooxygenases and out of scope for P450-monooxygenases. Especially the higher bond-strength of the methane C–H bond as compared to higher homologues was thought to be the major reason for this.¹⁵⁴ However, recently Reetz and coworkers have demonstrated that inert decoy molecules such as perfluorinated acids enable the P450BM3-catalysed hydroxylation of even methane.¹⁵⁵ It is thought that the perfluorinated alkyl chain ‘fills up’ the large cavity around the active site and thereby facilitates methane binding. The same approach (decoy molecules) was also successful in enhancing P450BM3-catalysed hydroxylation of e.g. benzene.^{156,181} It is also interesting to note that such decoy molecules may have an influence on the stereoselectivity of P450-catalysed oxyfunctionalisation reactions.¹⁸²

Next to protein engineering^{20,158,164,183–189} also substrate engineering may be a promising approach to improve P450-monooxygenase-catalysis as demonstrated by Griengl and coworkers.^{190–193} For example *Beauveria bassiana* cannot convert cyclopentanone whereas the corresponding *N*-benzoylspiro-oxazolidine was converted smoothly by the same organism (Scheme 13).


It was suggested that the starting material itself was not efficiently recognised by the monooxygenase. Also the nature of the temporary protecting group had an influence on the stereoselectivity of the hydroxylation reaction. So far, this approach has not found widespread and systematic investigation.

Another exciting new development in P450-chemistry is the recent finding by Arnold and coworkers that reduced (Fe^{II}) P450



Scheme 12 Engineered *Saccharomyces cerevisiae* overexpressing a P450 monooxygenase (CYP71AV1) for the selective (triple) oxygenation of amorpho-3,11-diene to artemisinic acid, a precursor for the anti-malaria drug artemisinin.





Scheme 13 Effect of temporary attachment of an oxazolizine protection group to cyclopentanone on the biohydroxylation by *B. bassiana*.

monooxygenases are efficient cyclopropanation catalysts (Scheme 14), opening up new avenues for P450-chemistry.¹⁵⁷

Table 2 gives a representative, yet naturally incomplete, overview over the diversity of P450 monooxygenase-catalysed oxyfunctionalisation reactions.

Peroxygenases entail the chemical versatility of P450 monooxygenases without being dependent on the complicated electron transport chains (*vide infra*). Instead of relying on reductive activation of molecular oxygen, peroxygenases utilise H_2O_2 to form the catalytically active oxyferryl species (hydrogen peroxide shunt in Scheme 9).¹⁹⁷

For many decades chloroperoxidase from *Caldariomyces fumago* (CPO) has been the role model and only representative of this highly interesting enzyme class.^{198–227} However, more recently a range of new (and potentially more useful) members of this enzyme class have gained interest.^{228–244} For example a peroxygenase from the basidiomycetous fungus *Agrocybe aegerita* is capable of cyclohexane hydroxylation, a reaction that has never been observed for CPO.²²⁸ If developed further, this reaction might become a viable alternative to the existing, selectivity-wise highly challenging chemical cyclohexane oxygenation reactions.¹⁵⁹

Even though peroxygenases are most valuable for the organic chemist due to their oxygen transfer capability (yielding *e.g.* enantiomerically pure epoxides or sulfoxides), some other – potentially very useful – applications have been reported recently. Haloperoxidases, for example, catalyse the oxidation of halogenides and release of the corresponding hypohalogenide into the reaction medium. Recently, Le Nôtre, Scott and coworkers reported a ‘biocatalytic’ oxidative decarboxylation of natural amino acids such as phenyl alanine yielding the corresponding nitriles as the major product (Scheme 15).²⁴⁵ The role of the vanadium peroxidase was restricted to *in situ* formation of hypochloride, which mediated the oxidative decarboxylation

of the α -amino acid. Compared to a stoichiometric use of bleach, this catalytic method excels by its catalytic use of chloride thereby significantly reducing salt wastes.

Some of us have applied CPO recently for the chemoenzymatic halogenation of thymol. The hydrogen peroxide needed for the enzymatic reaction was generated by electrochemical reduction of molecular oxygen (Scheme 16) thereby providing H_2O_2 in sufficient amounts to sustain the catalytic cycle while minimising H_2O_2 -related inactivation of the enzyme.


Overall, P450-enzymes (monooxygenases and peroxygenases) exhibit enormous potential for preparative organic synthesis.

Regeneration strategies

As mentioned above, reduced nicotinamides serve as universal electron donors for the reductive activation of molecular oxygen. Therefore, it is not very astonishing that the majority of published applications include NAD(P)H. Due to its fairly high costs, NAD(P)H cannot be applied in stoichiometric amounts but rather in catalytic amounts together with a suitable cofactor regeneration system (Table 3). Overall, oxidation of a simple sacrificial cosubstrate is utilised to promote monooxygenase catalysis.

One obvious approach is to utilise the microbial metabolism to provide the reducing equivalents needed.^{65,97,98,100,103–105,111–113,137,138,140,246–250} The advantages of this approach are: (1) the enzyme(s) are not isolated thereby significantly reducing the catalyst preparation costs,¹⁷⁶ the same is true for the nicotinamide cofactor, which is supplied by the microbial cell; (2) generally, enzymes within their natural environment (the microbial cell) are more stable than as isolated preparations, also the microbes can constantly replace inactivated enzymes; (3) the growth substrate (*e.g.* glucose) for the microorganism also serves as a sacrificial electron donor for the biotransformation reaction thereby theoretically providing the maximal amount of reducing equivalents available from complete mineralisation. These advantages explain why fermentative processes still dominate the field of biocatalytic oxyfunctionalisation chemistry. There are, however, also a range of challenges that have fostered research on the use of isolated enzymes. Amongst them are the frequently observed toxicity of the reagents to the microbial cells, transport limitations of reagents over the cell membranes, as well as issues related to undesired side reactions catalysed by the many other enzymes present in the microbial cells. Also, it is not always easy to balance the microorganism’s redox needs with the demands of the desired biotransformation.

Using isolated monooxygenases circumvents some of the aforementioned challenges: by utilising isolated enzymes, the



Scheme 14 Enzymatic cyclopropanation of styrene using a serine-mutant of P450BM3 (P411BM3-CIS).



Table 2 Representative examples of P450-catalysed oxyfunctionalisation reactions


Substrate	Product	Yield	Catalyst	ee (%)	Volumetric scale (aq only)	Remarks	Ref.
(1) CH bonds							
		n.d. (up to 3.3 mM product)	P450BM3 (purified enzyme)	—	1 mL	Perfluoro carboxylic acids as 'decoy' molecules	155 and 181
		n.d. (up to 67 mM product)	CYP153A6 (recombinant in E. coli)	Selectivity for 1-octanol = 94%	1 mL	$t = 24$ h	167
		Up to 90%	BM3 variants (purified enzymes)	—	1 mL	$[S]_0 = 200$ μ M; $t = 1$ h	194
		86% (up to 174 g L⁻¹)	Candida tropicalis	—	1 L	100–200 g L⁻¹	177
		30%	CYP153A6 (rec. in E. coli)	—	1 L	$t = 26$ h; whole-cell biocatalysts	166
		73%	P450 pyrvariant (rec. in E. coli)	94% (S) exclusive regioselectivity	0.5 mL	$[S]_0 = 4.5$ mM; $t = 9$ h	149
		86%	P450BM3 variants (rec. in E. coli)	> 99% (R) regioselectivity > 93%	50 mL	$t = 8$ h	195
		90%	P450BM3 variants (rec. in E. coli)	96–97% up to exclusive regioselectivity	100 mL	$[S]_0 = 1$ mM; $t = 24$ h	164
(2) Aromatic hydroxylations							
		n.d.	P450BM3 variants (purified enzymes)	Up to 90% selectivity (p- and benzyl-products)	1 mL	$[S]_0 = 5$ mM; $t = 24$ h use of decoy molecules	156
		n.d.	Beauveria bassiana				
(3) Epoxidations							
		42%	P450BM3 variants (rec in B. subtilis 3C5N)	27.8 (R)	10 mL		196
		90%	P450BM3 variants	97% ee (n.d.) exclusive regioselectivity	1 mL	$[S]_0 = 0.2$ mM	172

P450BM3: CYP102A1 from *Bacillus megaterium*; P450cam: CYP101 from *Pseudomonas putida*; P450pyr: from *Sphingomonas* sp. HXN-200; CYP152A1: from *Bacillus subtilis*; CYP152A2: from *Clostridium acetobutylicum*.

biotransformation is uncoupled from the fermentation step and therefore can be controlled more easily. Also, undesired side reactions are generally observed to a lesser extent than in whole-cell systems. The major challenge of using isolated enzymes is that the supply of the monooxygenase with reducing

equivalents does not anymore come along with the microbial metabolism. Hence, the nicotinamide cofactor (in substoichiometric amounts) has to be applied together with a *suitable in situ* regeneration system. Table 3 gives an overview on common enzymatic NAD(P)H regeneration systems used to promote





Scheme 15 Vanadium-haloperoxidase catalysed oxidative decarboxylation of phenylalanine.


Scheme 16 Chemoenzymatic halogenation of phenols (e.g. thymol) using CPO-generated hypochloride. H_2O_2 was obtained *in situ* from electrochemical O_2 reduction.

Table 3 Examples for enzymatic NAD(P)H regeneration systems used for monooxygenase reactions

Regeneration enzyme	Cosubstrate	Coproduct	Cofactor	Ref.
FDH	Formate	CO_2	NADH	86, 114, 173 and 251
ADH	Isopropanol	Acetone	NADPH	62 and 120
PDH	Phosphite	Phosphate	NAD(P)H	148, 252 and 253
G6PDH	Glucose-6-phosphate	Glucono-6-phosphate lactone	NAD(P)H	40 and 254–256

FDH: formate dehydrogenase; ADH: alcohol dehydrogenase; PDH: phosphite dehydrogenase; G6PDH: glucose-6-phosphate dehydrogenase.


monooxygenase reactions. To estimate the efficiency of a given regeneration system the total turnover number (TTN) of the nicotinamide cofactor can be used. As a rule of thumb, TTN of greater than 1000 are generally considered to be sufficient for an economically reasonable process (even though it must be mentioned here that this very much depends on the price of the product amongst others).

Recently, so-called designer cells have gained significant attention. This approach combines the advantages of whole cell biocatalysis and the regeneration approaches outlined in Table 3 by coexpressing the production enzyme together with a suitable regeneration system and using the whole cells as catalysts.^{120,252} On the one hand the enzymes are protected in their natural environment and also protein-isolation and -purification is not applied. On the other hand, the cells are usually not metabolically active thereby largely eliminating

toxicity issues as well as undesired side reactions. Overall, the designer-cell approach appears to be a very promising catalyst concept for future biocatalytic oxyfunctionalisation reactions.

The regeneration approaches outlined before all are based on the enzyme-coupled regeneration concept: regeneration reaction and production reaction are linked *via* the nicotinamide cofactor only. Hence, the cofactor regeneration consumes another substrate (cosubstrate) and produces a stoichiometric coproduct. Another interesting approach is the so-called intrasequential cascade, wherein the NAD(P)H-consuming (oxyfunctionalisation) reaction is also productively coupled to the NAD(P)H-regenerating reaction *via* an intermediate product (Scheme 17). Their use elegantly circumvents the need for the additional cosubstrate-coproduct couple by double transformation of only one substrate but naturally is rather limited in scope. However, the self-sufficient nature of these reactions as well as the apparent non-generation





Scheme 17 Examples of intrasequential oxyfunctionalisation sequences with the monooxygenase catalysing the second (A)^{162,163} or the first step (B)^{160,161} of the sequence.

of wastes might point towards bulk-scale application such as ϵ -caprolactone or cyclohexanone from simple starting materials.

Direct regeneration approaches

Many monooxygenases rely on rather complicated, multi-enzyme electron transport chains to deliver the reducing equivalents from NAD(P)H to the flavin- or heme-prosthetic group. While this architecture makes sense for the (microbial) cell as it adds further levels of control over the cellular redox metabolism, it adds further complexity to the application of monooxygenases for chemical synthesis. Often, only the reducing equivalents are needed to sustain the monooxygenases' catalytic cycles; therefore in recent years a growing number of research efforts have been dedicated to delivering the reducing equivalents directly to the monooxygenases and circumventing the electron transport chains (Scheme 18).


The potential benefit of such direct regeneration approaches is that complicated electron transport chains comprising up to 2 additional enzymes and 2 additional cofactors can be substituted by only one regeneration catalyst, resulting in highly simplified (and more easily controllable) reaction schemes.

Table 4 summarises some representative examples of oxyfunctionalisation reactions performed by direct regeneration.

It becomes clear from Table 4 that the immense potential of direct regeneration of monooxygenases still remains to be exploited.

The major limitation is the regeneration catalysts, which in most cases do not appear to act as true catalysts. We believe that the reason lies in the high reactivity of most mediators with molecular oxygen. Hence, futile reoxidation of the reduced regeneration catalysts by molecular oxygen competes with the desired monooxygenase regeneration thereby lowering the productive catalytic turnover of the regeneration catalysts. Furthermore, the futile cycle leads to the generation of reactive (partially reduced) oxygen species (ROS), which impair enzyme stability and lead to undesired side reactions.





The molecular reason for this undesired side reaction probably lies in the redox properties of the regeneration catalysts used. With the exception of $[\text{Cp}^*\text{Rh}(\text{bpy})(\text{H}_2\text{O})]^{2+}$ and deaza-flavin, all regeneration catalysts are obligate one electron donors; hence their reaction with the predominant triplet oxygen (${}^3\text{O}_2$) is spin-allowed (and fast) whereas the reactions of the two-electron donors ($[\text{Cp}^*\text{Rh}(\text{bpy})\text{H}]^+$ and deaza-flavin^{red}) with ${}^3\text{O}_2$ are spin-forbidden (and therefore slow). Also the natural redox mediators such as putida redoxin (Pdx) are single electron mediators and therefore prone to fast aerobic reoxidation. The same is true to some extent for reduced flavins. Even though they are traditionally denoted as two-electron donors (in the classical mechanisms) they are also able to form semiquinones *e.g.* during sequential reduction of FeS-redoxproteins or during fast synproportionation with oxidised flavins.²⁷⁴ This also explains the exceptionally high turnover numbers observed by Schmid and coworkers (Table 4).¹⁰¹



Scheme 18 Comparison of the 'traditional' regeneration of multi-component monooxygenases (upper) with the direct regeneration approach (lower). The flow of reducing equivalents is shown in bold blue.^{11,257,258}



Table 4 Examples for direct regeneration of monooxygenases

Product	Monooxygenase	Regeneration catalyst	Source of reducing equivalents	TTN (regeneration catalyst)	Ref.
	P450 cam	Pdx	Cathode	0.06	259
	StyA StyA Myoglobin	FAD [Cp*Rh(bpy)(H ₂ O)] ²⁺ None	Cathode NaHCO ₂ Cathode	Up to 700 10 —	101, 108 and 260 110 261 and 262
	P450 cam	Pdx	Cathode	0.51	263
	P450rFP45004A1	Co(sep)	Cathode	0.016	264
	P450BM3 P450BM3 P450BM3 P450BM3 – Ru-hybrid catalyst	Co(sep) [Cp ₂ Co] ⁺ Co(sep) Deazaflavin	Zn Cathode Zn Sodium diethyldithiocarbamate	<1 0.05 0.15 140	265 and 266 267 266 153 and 268
	P450BM3 P450BM3	Co(sep)	EDTA n.d.	7 Cathode	269 168 and 270–272
	P450 cin	Co(sep), phenosafranine T, neutral red, flavins	n.d.	Cathode	273

By using very low flavin concentrations they could efficiently shift the flavin synproportionation equilibrium away from the reactive flavin semiquinones. Furthermore the advanced electrochemical reactor setup enabled minimising the contact time of reduced flavins and molecular oxygen.

Unfortunately, so far this undesired uncoupling reaction (also observed quite frequently with the 'traditional' regeneration approaches) has not been addressed very much and a general awareness of this oxygen dilemma is missing.

Overall, it can be asserted that on the one hand undesired, spontaneous reduction of molecular oxygen leads to a waste of reducing equivalents and concomitant of toxic ROS. On the other hand, molecular oxygen, as an integral part of the catalytic cycle of monooxygenases, cannot be omitted from the reaction schemes, resulting in the 'oxygen dilemma'. Practical solutions to the oxygen dilemma are urgently needed in order to make monooxygenase-catalysis truly practical for organic synthesis.

Supply with H₂O₂ to promote peroxygenase catalysis

The dependence of peroxygenases on simple peroxides only at first sight offers a trouble-free catalyst system to be used in organic synthesis. The major challenge of using peroxides as a source of oxygen lies in their reactivity, especially with the prosthetic heme group itself. The exact inactivation mechanism is still under debate but it is clear by now that already small concentrations of hydrogen peroxide irreversibly inactivate the heme group (most probably oxidatively).²⁷⁵

The simplest approach to circumvent the undesired oxidative inactivation of peroxygenases is to supply H₂O₂ in various, small

portions. This approach is, however, work-intensive and also leads to significant volume increases which will complicate downstream processing. Alternatively, organic hydroperoxides have received some attention as milder alternatives to H₂O₂.¹⁹⁷ More recently, various *in situ* O₂ reduction methods have been evaluated to generate H₂O₂. The principle behind is that these methods enable to generate H₂O₂ *in situ* in just the right amounts to sustain peroxygenase catalysis while minimising the H₂O₂ related inactivation. Table 5 gives an overview of the different sources of reducing equivalents needed for O₂ reduction and catalysts used.

Each H₂O₂ generation method has specific advantages and disadvantages. For example, cathodic reduction of molecular oxygen represents a potentially very simple and environmentally benign approach, but also requires specialised equipment. Glucose oxidase mediated reduction of O₂ is simple and easy to apply, however gluconic acid accumulates in stoichiometric amounts leading to challenges in pH control. Overall, 'the ideal' *in situ* H₂O₂ generation does not exist and a suitable method has to be established for every peroxygenase reaction.

How green/environmentally friendly are biocatalytic oxyfunctionalisation reactions?

Today, biocatalysis is generally accepted as a 'green technology'. Often, one or a few of the famous Twelve Principles of Green Chemistry²⁸⁸ are used to substantiate the green touch of a given



Table 5 *In situ* H₂O₂ generation methods to promote peroxygenase reactions

Catalyst	Cosubstrate	Coproduct	Ref.
		Catalyst	Peroxygenase
GOx	Glucose	Gluconolactone	197, 211 and 276–279
Cathode	—	—	201 and 280–284
Pd	H ₂	—	285
Flavin/hν	EDTA	Ethylene diamine, CO ₂ , formaldehyde	228, 286 and 287

GOx: Glucose oxidase.

biocatalytic reaction. However, we are convinced that authors should be more careful with green claims as a critical evaluation of the environmental impact might actually result in nasty surprises. The Twelve Principles of Green Chemistry are a wonderful framework for the design of environmentally more friendly processes but simple adherence to some of these principles does not make a given reaction/process 'green'. Therefore, a more quantitative (and critical) evaluation is a prerequisite *en route* to truly Green Chemistry. Today, full life cycle assessment, taking into account as many parameters as possible, represents the 'golden standard' of environmental evaluation. However, the data basis required for LCAs is enormous, making LCAs time-consuming and too expensive for academics to perform.

We believe that simple, mass-based metrics such as the E-factor (*E* being the amount of waste generated per kg of product)²⁸⁹ may be a valuable tool especially for academic researchers to estimate the 'greenness' of a given reaction.^{290–293} The E-factor concept is easily understood and the calculations easily and quickly done. Of course, such a simple mass-based tool neglects important contributors to the environmental impact such as energy consumption and does not weigh the quality of the different mass flows (scarce starting materials, hazardous wastes).^{294,295} Nevertheless, the E-factor frequently qualitatively points into the same direction as more advanced analyses and thereby can give valuable hints to optimise a reaction.^{100,290,296} Therefore, we would like to encourage especially academic researchers to use this simple tool more often to critically assess the environmental impact of their reactions.

In the following, we highlight and discuss two Green Chemistry issues that – to our mind – are notoriously underestimated in the scientific literature dealing with (bio)catalytic oxyfunctionalisation chemistry: substrate loading and downstream processing.

Substrate loading has a very significant impact on the economic feasibility and environmental impact of a reaction. However, the majority of reactants of interest is poorly water soluble. Unfortunately, the general solution to this challenge is to apply the starting material in low concentrations (often in the lower millimolar range). A simple E-factor estimation however demonstrates the dimensions of the water ballast resulting from this (Fig. 1). Producing tons of contaminated waste water per kg of product cannot be the ultimate green (not to mention economical) solution.





Fig. 1 Water consumption at different reactant concentrations (expressed as kg(wastewater) per kg(product)). Black line: theoretical Water-E-factor (assumption $M(\text{product}) = 200 \text{ g mol}^{-1}$, full conversion); red diamonds: experimental Water-E-factors from published monooxygenase reactions.²⁹⁰ The examples with higher than expected E-factors are those with incomplete conversion.

Increasing the overall substrate concentration can significantly reduce the water ballast of any given reaction and therefore should be more often be strived for. To cope with the poor substrate solubility, the two-liquid-phase-system (2LPS) approach seems to be a viable solution. Here, a water-immiscible apolar organic phase serves as the substrate reservoir and product sink enabling overall high payloads (Scheme 19).

Additional benefits from the 2LPS concept may be alleviation of reactant toxicities and inhibitory effects (especially for whole cell biocatalysts),^{100,297} prevention of over-oxidation (e.g. of aldehydes into carboxylic acids),^{11,100,246,297–303} and prevention of hydrolytic degradation of e.g. epoxide or lactone products.^{14,111,112,114,304–306} Furthermore, high product concentrations in easily water separable organic phases will also facilitate DSP (*vide infra*).

Of course, the selection of the organic solvent should – next to practical issues such as partitioning coefficients and biocatalyst stability – also take its potential environmental impact into account.^{307–309}





Scheme 19 The two-liquid phase system (2LPS) approach. A hydrophobic organic phase solubilises overall high amounts of the hydrophobic reactants. From there, the substrate partitions into the aqueous, oxygenase-containing aqueous phase to be converted. The product, again, partitions between both phases and thereby is largely extracted into the organic layer.

One issue of 2LPS arises from the rather hydrophilic character of many sacrificial electron donors used such as formates, phosphites or glucose making them incompatible with 2LPSs exhibiting high volumetric ratios of organic to aqueous phase. To solve this challenge, some of us have recently proposed using hydrophobised formates as the organic phase for biocatalytic oxyfunctionalisation reactions (Scheme 20).²⁵¹

Downstream processing (DSP) is an issue that is not very frequently addressed in typical publications dealing


with (bio)catalysis. However, DSP is an integral part of the production system as 'it is no product unless it is in a bottle' (C. Wandrey). From an environmental point-of-view, DSP can contribute very significantly to the overall environmental impact of a production system.^{290,310} Therefore, an increased focus on DSP issues also at an early stage of development is highly desirable. This should include 'smart by design' reaction systems enabling facile product isolation *e.g.* by filtration or 2LPSs enabling low-energy distillation DSP.

Another very promising line of research comprises so-called cascade reactions,^{311,312} wherein complex reaction sequences are performed without isolation of the intermediate reaction products. A very elegant cascade was reported recently by Bühler and coworkers reporting a formal terminal amination of fatty acids by combining a sequence of two hydroxylase- and one transaminase-reaction (together with the corresponding cofactor regeneration reactions) in one engineered *E. coli* production strain (Scheme 21).^{313,314}


Today, still too many research projects on biocatalytic oxyfunctionalisation focus on the biocatalyst only while accepting low substrate loadings and completely neglecting the DSP part.

Conclusions

Biocatalysis has a lot to offer for the organic chemist. Simple and robust catalysts such as lipases for chirotechnology applications are well-established already. Oxygenases are on the go to follow them. This will significantly broaden the chemist's toolbox for selective oxidation/oxyfunctionalisation reactions. Especially the high selectivity of enzymes will enable shorter



Scheme 20 Hydrophobic formic acid esters as the reactive organic phase serving as the substrate reservoir/product sink and source of reducing equivalents for FDH-catalysed NADH regeneration.



Scheme 21 Cascade combining AlkB and ω -TA in recombinant *E. coli*.^{313,314}

synthesis routes and yield higher quality products. Another interesting feature of biocatalysis (in general) is its potential for environmentally more benign syntheses. However, being biobased alone does not make an enzymatic route green, a more self-critical evaluation of contributors is highly desirable. In this respect, already simple metrics such as the E-factor may be valuable and simple tools.

Acknowledgements

This work was supported by the European Union through CMST COST Action CM1003 (Biological oxidation reactions – mechanisms and design of new catalysts).

References

- 1 E. Roduner, W. Kaim, B. Sarkar, V. B. Urlacher, J. Pleiss, R. Gläser, W.-D. Einicke, G. A. Sprenger, U. Beifuß, E. Klemm, C. Liebner, H. Hieronymus, S.-F. Hsu, B. Plietker and S. Laschat, *ChemCatChem*, 2013, **5**, 82–112.
- 2 H. Mayr and A. R. Ofal, *Angew. Chem., Int. Ed.*, 2006, **45**, 1844–1854.
- 3 R. B. Silverman, *The Organic Chemistry of Enzyme-Catalyzed Reactions*, Academic Press, San Diego, 2000.
- 4 U. Bornscheuer and R. Kazlauskas, *Hydrolases in Organic Synthesis*, Wiley-VCH, Weinheim, 2006.
- 5 *Enzyme Catalysis in Organic Synthesis*, ed. K. Drauz, H. Groeger and O. May, Wiley-VCH, Weinheim, 2012.
- 6 K. Faber, *Biotransformations in Organic Chemistry*, Springer, Berlin, 2011.
- 7 W. Kroutil, H. Mang, K. Edeger and K. Faber, *Curr. Opin. Chem. Biol.*, 2004, **8**, 120–126.
- 8 W. Kroutil, H. Mang, K. Edeger and K. Faber, *Adv. Synth. Catal.*, 2004, **346**, 125–142.
- 9 B. M. Nestl, S. C. Hammer, B. A. Nebel and B. Hauer, *Angew. Chem., Int. Ed.*, 2014, **53**, 3070–3095.
- 10 U. T. Bornscheuer, G. W. Huisman, R. J. Kazlauskas, S. Lutz, J. C. Moore and K. Robins, *Nature*, 2012, **485**, 185–194.
- 11 F. Hollmann, I. W. C. E. Arends, K. Buehler, A. Schallmey and B. Bühler, *Green Chem.*, 2011, **13**, 226–265.
- 12 L. M. Blank, B. E. Ebert, K. Buehler and B. Bühler, *Antioxid. Redox Signaling*, 2010, **13**, 349–394.
- 13 E. G. Funhoff and J. B. Van Beilen, *Biocatal. Biotransform.*, 2007, **25**, 186–193.
- 14 J. B. van Beilen, W. A. Duetz, A. Schmid and B. Witholt, *Trends Biotechnol.*, 2003, **21**, 170–177.
- 15 R. J. Kazlauskas and U. T. Bornscheuer, *Nat. Chem. Biol.*, 2009, **5**, 526–529.
- 16 M. T. Reetz, *J. Am. Chem. Soc.*, 2013, **135**, 12480–12496.
- 17 M. T. Reetz, *Tetrahedron*, 2012, **68**, 7530–7548.
- 18 M. T. Reetz, *Angew. Chem., Int. Ed.*, 2011, **50**, 138–174.
- 19 J. C. Lewis, S. M. Mantovani, Y. Fu, C. D. Snow, R. S. Komor, C.-H. Wong and F. H. Arnold, *ChemBioChem*, 2011, **11**, 2502–2505.
- 20 S. T. Jung, R. Lauchli and F. H. Arnold, *Curr. Opin. Biotechnol.*, 2011, **22**, 809–817.
- 21 V. B. Urlacher and M. Girhard, *Trends Biotechnol.*, 2012, **30**, 26–36.
- 22 V. B. Urlacher and S. Eiben, *Trends Biotechnol.*, 2006, **24**, 324–330.
- 23 V. Urlacher and R. D. Schmid, *Curr. Opin. Biotechnol.*, 2002, **13**, 557–564.
- 24 L. G. Otten, F. Hollmann and I. W. C. E. Arends, *Trends Biotechnol.*, 2010, **28**, 46–54.
- 25 D. J. Leak, R. A. Sheldon, J. M. Woodley and P. Adlercreutz, *Biocatal. Biotransform.*, 2009, **27**, 1–26.
- 26 M. K. Julsing, S. Cornelissen, B. Bühler and A. Schmid, *Curr. Opin. Chem. Biol.*, 2008, **12**, 177–186.
- 27 W. Dijkman, G. Gonzalo, A. Mattevi and M. W. Fraaije, *Appl. Microbiol. Biotechnol.*, 2013, **97**, 5177–5188.
- 28 G. de Gonzalo and M. W. Fraaije, *ChemCatChem*, 2012, **5**, 403–415.
- 29 D. E. Torres Pazmiño, M. Winkler, A. Glieder and M. W. Fraaije, *J. Biotechnol.*, 2010, **146**, 9–24.
- 30 G. de Gonzalo, M. D. Mihovilovic and M. W. Fraaije, *ChemBioChem*, 2010, **11**, 2208–2231.
- 31 W. J. H. van Berkel, N. M. Kamerbeek and M. W. Fraaije, *J. Biotechnol.*, 2006, **124**, 670–689.
- 32 S. Montersino, D. Tischler, G. T. Gassner and W. J. H. v. Berkel, *Adv. Synth. Catal.*, 2011, **353**, 2301–2319.
- 33 N. M. Kamerbeek, D. B. Janssen, W. J. H. van Berkel and M. W. Fraaije, *Adv. Synth. Catal.*, 2003, **345**, 667–678.
- 34 M. Hofrichter, R. Ullrich, M. J. Pecyna, C. Liers and T. Lundell, *Appl. Microbiol. Biotechnol.*, 2010, **87**, 871–897.
- 35 M. Hofrichter and R. Ullrich, *Appl. Microbiol. Biotechnol.*, 2006, **71**, 276–288.
- 36 K. Balke, M. Kadow, H. Mallin, S. Sass and U. T. Bornscheuer, *Org. Biomol. Chem.*, 2012, **10**, 6249–6265.
- 37 A. Riebel, G. de Gonzalo and M. W. Fraaije, *J. Mol. Catal. B: Enzym.*, 2013, **88**, 20–25.
- 38 H. L. van Beek, G. d. Gonzalo and M. W. Fraaije, *Chem. Commun.*, 2012, **48**, 3288–3290.
- 39 D. E. Torres Pazmiño, H. M. Dudek and M. W. Fraaije, *Curr. Opin. Chem. Biol.*, 2010, **14**, 138–144.
- 40 G. de Gonzalo, G. Ottolina, F. Zambianchi, M. W. Fraaije and G. Carrea, *J. Mol. Catal. B: Enzym.*, 2006, **39**, 91–97.
- 41 R. Teufel, A. Miyanaga, Q. Michaudel, F. Stull, G. Louie, J. P. Noel, P. S. Baran, B. Palley and B. S. Moore, *Nature*, 2013, **503**, 552–556.
- 42 G. de Gonzalo, C. Smit, J. F. Jin, A. J. Minnaard and M. W. Fraaije, *Chem. Commun.*, 2011, **47**, 11050–11052.
- 43 G. E. Turfitt, *Biochem. J.*, 1948, **42**, 376–383.
- 44 J. Fried, R. W. Thoma and A. Klingsberg, *J. Am. Chem. Soc.*, 1953, **75**, 5764–5765.
- 45 D. H. Peterson, S. H. Eppstein, P. D. Meister, H. C. Murray, H. M. Leigh, A. Weintraub and L. M. Reineke, *J. Am. Chem. Soc.*, 1953, **75**, 5768–5769.
- 46 M. Griffin and P. W. Trudgill, *Eur. J. Biochem.*, 1976, **63**, 199–209.
- 47 N. A. Donoghue, D. B. Norris and P. W. Trudgill, *Eur. J. Biochem.*, 1976, **63**, 175–192.
- 48 C. T. Walsh and Y. C. J. Chen, *Angew. Chem., Int. Ed.*, 1988, **27**, 333–343.
- 49 M. D. Mihovilovic, B. Muller and P. Stanetty, *Eur. J. Org. Chem.*, 2002, 3711–3730.
- 50 J. D. Stewart, *Curr. Org. Chem.*, 1998, **2**, 195–216.
- 51 E. Malito, A. Alfieri, M. W. Fraaije and A. Mattevi, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 13157–13162.
- 52 A. Alfieri, E. Malito, R. Orru, M. W. Fraaije and A. Mattevi, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 6572–6577.
- 53 R. Baron, C. Riley, P. Chenprakhon, K. Thotsaporn, R. T. Winter, A. Alfieri, F. Forneris, W. J. H. van Berkel, P. Chaiyen, M. W. Fraaije, A. Mattevi and J. A. McCammon, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 10603–10608.
- 54 A. Kirschner and U. T. Bornscheuer, *Appl. Microbiol. Biotechnol.*, 2008, **81**, 465–472.
- 55 I. Polyak, M. T. Reetz and W. Thiel, *J. Phys. Chem. B*, 2013, **117**, 4993–5001.
- 56 L. P. Parra, R. Agudo and M. T. Reetz, *ChemBioChem*, 2013, **14**, 2301–2309.
- 57 Z.-G. Zhang, G.-D. Roiban, J. P. Acevedo, I. Polyak and M. T. Reetz, *Adv. Synth. Catal.*, 2013, **355**, 99–106.
- 58 Z.-G. Zhang, L. P. Parra and M. T. Reetz, *Chem. – Eur. J.*, 2012, **18**, 10160–10172.
- 59 S. Wu, J. P. Acevedo and M. T. Reetz, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 2775–2780.
- 60 D. J. Opperman and M. T. Reetz, *ChemBioChem*, 2010, **11**, 2589–2596.
- 61 M. T. Reetz and S. Wu, *J. Am. Chem. Soc.*, 2009, **131**, 15424–15432.
- 62 F. Schulz, F. Leca, F. Hollmann and M. T. Reetz, *Beilstein J. Org. Chem.*, 2005, **1**, 10, DOI: 10.1186/1860-5397-1-10.
- 63 M. Bocola, F. Schulz, F. Leca, A. Vogel, M. W. Fraaije and M. T. Reetz, *Adv. Synth. Catal.*, 2005, **347**, 979–986.
- 64 M. T. Reetz, B. Brunner, T. Schneider, F. Schulz, C. M. Clouthier and M. M. Kayser, *Angew. Chem., Int. Ed.*, 2004, **43**, 4075–4078.
- 65 I. Hilker, M. C. Gutierrez, R. Furstoss, J. Ward, R. Wohlgemuth and V. Alphand, *Nat. Protoc.*, 2008, **3**, 546–554.
- 66 I. Hilker, R. Wohlgemuth, V. Alphand and R. Furstoss, *Biotechnol. Bioeng.*, 2005, **92**, 702–710.



67 W. H. Lee, J. B. Park, K. Park, M. D. Kim and J. H. Seo, *Appl. Microbiol. Biotechnol.*, 2007, **76**, 329–338.

68 E. H. Doo, W. H. Lee, H. S. Seo, J. H. Seo and J. B. Park, *J. Biotechnol.*, 2009, **142**, 164–169.

69 S. Bisagni, B. Summers, S. Kara, R. Hatti-Kaul, G. Grogan, G. Mamo and F. Hollmann, *Top. Catal.*, 2014, **57**, 366–375.

70 C. N. Jensen, J. Cartwright, J. Ward, S. Hart, J. P. Turkenburg, S. T. Ali, M. J. Allen and G. Grogan, *ChemBioChem*, 2012, **13**, 872–878.

71 C. Rodriguez, G. de Gonzalo and V. Gotor, *J. Mol. Catal. B: Enzym.*, 2011, **74**, 138–143.

72 A. Rioz-Martinez, M. Kopacz, G. de Gonzalo, D. E. Torres Pazmino, V. Gotor and M. W. Fraaije, *Org. Biomol. Chem.*, 2011, **9**, 1337–1341.

73 V. Alphand and R. Wohlgemuth, *Curr. Org. Chem.*, 2011, **14**, 1928–1965.

74 J. Zhu, Y. K. Bong, S. J. Collier, M. Vogel, M. J. Nazor, D. Smith, S. Song, M. D. Clay, B. Mijts and X. Zhang, *Int. Patent Application to Codexis Inc.*, 2011.

75 P. B. Brondani, N. M. A. F. Guilmoto, H. M. Dudek, M. W. Fraaije and L. H. Andrade, *Tetrahedron*, 2012, **68**, 10431–10436.

76 L. H. Andrade, E. C. Pedrozo, H. G. Leite and P. B. Brondani, *J. Mol. Catal. B: Enzym.*, 2011, **73**, 63–66.

77 J. A. Latham, B. P. Branchaud, Y. C. J. Chen and C. Walsh, *J. Chem. Soc., Chem. Commun.*, 1986, 528–530.

78 B. P. Branchaud and C. T. Walsh, *J. Am. Chem. Soc.*, 1985, **107**, 2153–2161.

79 P. B. Brondani, G. de Gonzalo, M. W. Fraaije and L. H. Andrade, *Adv. Synth. Catal.*, 2011, **353**, 2169–2173.

80 Y. K. Bong, M. D. Clay, S. J. Collier, B. Mijts, M. Vogel, X. Zhang, J. Zhu, J. Nazor, D. Smith and S. Song, *Codexis*, 2011.

81 M. J. H. Moonen, M. W. Fraaije, I. M. C. M. Rietjens, C. Laane and W. J. H. van Berkel, *Adv. Synth. Catal.*, 2002, **344**, 1023–1035.

82 A. Meyer, M. Held, A. Schmid, H. P. E. Kohler and B. Witholt, *Biotechnol. Bioeng.*, 2003, **81**, 518–524.

83 A. Meyer, M. Wursten, A. Schmid, H. P. E. Kohler and B. Witholt, *J. Biol. Chem.*, 2002, **277**, 34161–34167.

84 A. Meyer, A. Schmid, M. Held, A. H. Westphal, M. Rothlisberger, H. P. E. Kohler, W. J. H. van Berkel and B. Witholt, *J. Biol. Chem.*, 2002, **277**, 5575–5582.

85 J. Lutz, V. V. Mozhaev, Y. L. Khmelnitsky, B. Witholt and A. Schmid, *J. Mol. Catal. B: Enzym.*, 2002, **19–20**, 177–187.

86 A. Schmid, I. Vereyken, M. Held and B. Witholt, *J. Mol. Catal. B: Enzym.*, 2001, **11**, 455–462.

87 A. Schmid, H. P. E. Kohler and K. H. Engesser, *J. Mol. Catal. B: Enzym.*, 1998, **5**, 311–316.

88 M. Held, W. Suske, A. Schmid, K. H. Engesser, H. P. E. Kohler, B. Witholt and M. G. Wubbolts, *J. Mol. Catal. B: Enzym.*, 1998, **5**, 87–93.

89 W. A. Suske, M. Held, A. Schmid, T. Fleischmann, M. G. Wubbolts and H.-P. E. Kohler, *J. Biol. Chem.*, 1997, **272**, 24257–24265.

90 E. Orenes-Pinero, F. Garcia-Carmona and A. Sanchez-Ferrer, *Food Chem.*, 2013, **139**, 377–383.

91 L. Saa, A. Jaureguibetia, E. Largo, M. J. Llama and J. L. Serra, *Appl. Microbiol. Biotechnol.*, 2010, **86**, 201–211.

92 U. Kirchner, A. H. Westphal, R. Muller and W. J. H. van Berkel, *J. Biol. Chem.*, 2003, **278**, 47545–47553.

93 F. M. Duffner, U. Kirchner, M. P. Bauer and R. Müller, *Gene*, 2000, **256**, 215–221.

94 J. Sucharitakul, C. Tongsook, D. Pakotiprapha, W. J. H. van Berkel and P. Chaiyen, *J. Biol. Chem.*, 2013, **288**, 35210–35221.

95 B. Entsch and W. J. H. Vanberkel, *FASEB J.*, 1995, **9**, 476–483.

96 S. Montersino and W. J. H. van Berkel, *Biochim. Biophys. Acta, Proteins Proteomics*, 2012, **1824**, 433–442.

97 R. Gross, K. Buehler and A. Schmid, *Biotechnol. Bioeng.*, 2013, **110**, 424–436.

98 M. K. Julsing, D. Kuhn, A. Schmid and B. Bühler, *Biotechnol. Bioeng.*, 2012, **109**, 1109–1119.

99 R. Ruinatscha, R. Karande, K. Buehler and A. Schmid, *Molecules*, 2011, **16**, 5975–5988.

100 D. Kuhn, M. A. Khaliq, E. Heinzle, B. Bühler and A. Schmid, *Green Chem.*, 2010, **12**, 815–827.

101 R. Ruinatscha, C. Dusny, K. Buehler and A. Schmid, *Adv. Synth. Catal.*, 2009, **351**, 2505–2515.

102 R. Gross, K. Lang, K. Bühler and A. Schmid, *Biotechnol. Bioeng.*, 2009, **105**, 705–717.

103 B. Buehler, J. B. Park, L. M. Blank and A. Schmid, *Appl. Environ. Microbiol.*, 2008, **74**, 1436–1446.

104 L. M. Blank, B. E. Ebert, B. Bühler and A. Schmid, *Biotechnol. Bioeng.*, 2008, **100**, 1050–1065.

105 J. B. Park, B. Bühler, S. Panke, B. Witholt and A. Schmid, *Biotechnol. Bioeng.*, 2007, **98**, 1219–1229.

106 J. B. Park, B. Bühler, T. Habicher, B. Hauer, S. Panke, B. Witholt and A. Schmid, *Biotechnol. Bioeng.*, 2006, **95**, 501–512.

107 K. A. Feenstra, K. Hofstetter, R. Bosch, A. Schmid, J. N. M. Commandeur and N. P. E. Vermeulen, *Biophys. J.*, 2006, **91**, 3206–3216.

108 F. Hollmann, K. Hofstetter, T. Habicher, B. Hauer and A. Schmid, *J. Am. Chem. Soc.*, 2005, **127**, 6540–6541.

109 K. Otto, K. Hofstetter, M. Rothlisberger, B. Witholt and A. Schmid, *J. Bacteriol.*, 2004, **186**, 5292–5302.

110 F. Hollmann, P. C. Lin, B. Witholt and A. Schmid, *J. Am. Chem. Soc.*, 2003, **125**, 8209–8217.

111 S. Panke, M. Held, M. G. Wubbolts, B. Witholt and A. Schmid, *Biotechnol. Bioeng.*, 2002, **80**, 33–41.

112 A. Schmid, K. Hofstetter, H.-J. Feiten, F. Hollmann and B. Witholt, *Adv. Synth. Catal.*, 2001, **343**, 732–737.

113 S. Panke, M. G. Wubbolts, A. Schmid and B. Witholt, *Biotechnol. Bioeng.*, 2000, **69**, 91–100.

114 K. Hofstetter, J. Lutz, I. Lang, B. Witholt and A. Schmid, *Angew. Chem., Int. Ed.*, 2004, **43**, 2163–2166.

115 D. Tischler, M. Schlömann, W. J. H. van Berkel and G. T. Gassner, *FEBS Lett.*, 2013, **587**, 3848–3852.

116 D. Tischler, J. A. D. Groning, S. R. Kaschabek and M. Schlömann, *Appl. Biochem. Biotechnol.*, 2012, **167**, 931–944.

117 D. Tischler, R. Kermér, J. A. D. Groning, S. R. Kaschabek, W. J. H. van Berkel and M. Schlömann, *J. Bacteriol.*, 2010, **192**, 5220–5227.

118 D. Tischler, D. Eulberg, S. Lakner, S. R. Kaschabek, W. J. H. van Berkel and M. Schlömann, *J. Bacteriol.*, 2009, **191**, 4996–5009.

119 H. Toda, R. Imae, T. Komio and N. Itoh, *Appl. Microbiol. Biotechnol.*, 2012, **96**, 407–418.

120 H. Toda, R. Imae and N. Itoh, *Tetrahedron: Asymmetry*, 2012, **23**, 1542–1549.

121 E. W. van Hellemond, D. B. Janssen and M. W. Fraaije, *Appl. Environ. Microbiol.*, 2007, **73**, 5832–5839.

122 R. McKenna, S. Pugh, B. Thompson and D. R. Nielsen, *Biotechnol. J.*, 2013, **8**, 1465–1475.

123 K.-H. van Pee, *Curr. Org. Chem.*, 2012, **16**, 2583–2597.

124 K. H. van Pee, *ChemBioChem*, 2011, **12**, 681–683.

125 A. Lang, S. Polnick, T. Nicke, P. William, E. P. Patallo, J. H. Naismith and K. H. van Pee, *Angew. Chem., Int. Ed.*, 2011, **50**, 2951–2953.

126 X. F. Zhu, W. De Laurentis, K. Leang, J. Herrmann, K. Lhiefeld, K. H. van Pee and J. H. Naismith, *J. Mol. Biol.*, 2009, **391**, 74–85.

127 S. Flecks, E. R. Patallo, X. F. Zhu, A. J. Ernyei, G. Seifert, A. Schneider, C. J. Dong, J. H. Naismith and K. H. van Pee, *Angew. Chem., Int. Ed.*, 2008, **47**, 9533–9536.

128 X. P. Chen and K. H. van Pee, *Acta Biochim. Biophys. Sin.*, 2008, **40**, 183–193.

129 K. H. van Pee and E. P. Patallo, *Appl. Microbiol. Biotechnol.*, 2006, **70**, 631–641.

130 C. Seibold, H. Schnerr, J. Rumpf, A. Kunzendorf, C. Hatscher, T. Wage, A. J. Ernyei, C. J. Dong, J. H. Naismith and K. H. van Pee, *Biocatal. Biotransform.*, 2006, **24**, 401–408.

131 S. Unversucht, F. Hollmann, A. Schmid and K.-H. van Pee, *Adv. Synth. Catal.*, 2005, **347**, 1163–1167.

132 C. J. Dong, S. Flecks, S. Unversucht, C. Haupt, K. H. van Pee and J. H. Naismith, *Science*, 2005, **309**, 2216–2219.

133 S. Keller, T. Wage, K. Hohaus, M. Hölzer, E. Eichhorn and K.-H. van Pee, *Angew. Chem., Int. Ed.*, 2000, **39**, 2300–2302.

134 M. Frese, P. H. Guzowska, H. Voß and N. Sewald, *ChemCatChem*, 2014, **6**, 1270–1276.

135 Y. Dong, J. Yan, H. Du, M. Chen, T. Ma and L. Feng, *Appl. Microbiol. Biotechnol.*, 2012, **94**, 1019–1029.

136 L. Li, X. Liu, W. Yang, F. Xu, W. Wang, L. Feng, M. Bartlam, L. Wang and Z. Rao, *J. Mol. Biol.*, 2008, **376**, 453–465.



137 H. Lin, J. Qiao, Y. Liu and Z. L. Wu, *J. Mol. Catal. B: Enzym.*, 2011, **67**, 236–241.

138 H. Lin, Y. Liu and Z.-L. Wu, *Tetrahedron: Asymmetry*, 2011, **22**, 134–137.

139 S. Colonna, N. Gaggero, G. Carrea, G. Ottolina, P. Pasta and F. Zambianchi, *Tetrahedron Lett.*, 2002, **43**, 1797–1799.

140 C. V. F. Baldwin, R. Wohlgemuth and J. M. Woodley, *Org. Process Res. Dev.*, 2008, **12**, 660–665.

141 K. Geitner, A. Kirschner, J. Rehdorf, M. Schmidt, M. D. Mihovilovic and U. T. Bornscheuer, *Tetrahedron: Asymmetry*, 2007, **18**, 892–895.

142 J. D. Stewart, K. W. Reed, C. A. Martinez, J. Zhu, G. Chen and M. M. Kayser, *J. Am. Chem. Soc.*, 1998, **120**, 3541–3548.

143 S. Kara, D. Spickermann, J. H. Schrittwieser, C. Leggewie, W. J. H. Van Berkel, I. W. C. E. Arends and F. Hollmann, *Green Chem.*, 2013, **15**, 330–335.

144 C. J. C. Whitehouse, S. G. Bell and L.-L. Wong, *Chem. Soc. Rev.*, 2012, **41**, 1218–1260.

145 R. Fasan, *ACS Catal.*, 2012, **2**, 647–666.

146 E. O'Reilly, V. Kohler, S. L. Flitsch and N. J. Turner, *Chem. Commun.*, 2011, **47**, 2490–2501.

147 G. Grogan, *Curr. Opin. Chem. Biol.*, 2011, **15**, 241–248.

148 H. Watanabe, H. Hirakawa and T. Nagamune, *ChemCatChem*, 2013, **5**, 3835–3840.

149 S. Q. Pham, P. Gao and Z. Li, *Biotechnol. Bioeng.*, 2013, **110**, 363–373.

150 S. H. Lee, Y.-C. Kwon, D.-M. Kim and C. B. Park, *Biotechnol. Bioeng.*, 2013, **110**, 383–390.

151 M. Girhard, E. Kunigk, S. Tihovsky, V. V. Shumyantseva and V. B. Urlacher, *Biotechnol. Appl. Biochem.*, 2013, **60**, 111–118.

152 D. Zehentgruber, V. B. Urlacher and S. Lütz, *J. Mol. Catal. B: Enzym.*, 2012, **84**, 62–64.

153 N.-H. Tran, N. Huynh, G. Chavez, A. Nguyen, S. Dwaraknath, T.-A. Nguyen, M. Nguyen and L. Cheruzel, *J. Inorg. Biochem.*, 2012, **115**, 50–56.

154 M. M. Chen, P. S. Coelho and F. H. Arnold, *Adv. Synth. Catal.*, 2012, **354**, 964–968.

155 F. E. Zilly, J. P. Acevedo, W. Augustyniak, A. Dege, U. W. Häusig and M. T. Reetz, *Angew. Chem., Int. Ed.*, 2011, **50**, 2720–2724.

156 O. Shoji, T. Kunitatsu, N. Kawakami and Y. Watanabe, *Angew. Chem., Int. Ed.*, 2013, **52**, 6606–6610.

157 P. S. Coelho, Z. J. Wang, M. E. Ener, S. A. Baril, A. Kannan, F. H. Arnold and E. M. Brustad, *Nat. Chem. Biol.*, 2013, **9**, 485–487.

158 H. Joo, Z. L. Lin and F. H. Arnold, *Nature*, 1999, **399**, 670–673.

159 M. T. Musser, *Ullmann's Encyclopedia of Industrial Chemistry*, Wiley-VCH Verlag GmbH & Co. KGaA, 2000.

160 S. Staudt, E. Burda, C. Giese, C. A. Müller, J. Marienhagen, U. Schwaneberg, W. Hummel, K. Drauz and H. Gröger, *Angew. Chem., Int. Ed.*, 2013, **52**, 2359–2363.

161 C. A. Müller, B. Akkapurathu, T. Winkler, S. Staudt, W. Hummel, H. Gröger and U. Schwaneberg, *Adv. Synth. Catal.*, 2013, **355**, 1787–1798.

162 A. J. Willetts, C. J. Knowles, M. S. Levitt, S. M. Roberts, H. Sandey and N. F. Shipston, *J. Chem. Soc., Perkin Trans. 1*, 1991, 1608–1610.

163 H. Mallin, H. Wulf and U. T. Bornscheuer, *Enzyme Microb. Technol.*, 2013, **53**, 283–287.

164 S. Kille, F. E. Zilly, J. P. Acevedo and M. T. Reetz, *Nat. Chem.*, 2011, **3**, 738–743.

165 D. Zehentgruber, F. Hannemann, S. Bleif, R. Bernhardt and S. Lütz, *ChemBioChem*, 2010, **11**, 713–721.

166 S. Cornelissen, M. K. Julsing, J. Volmer, O. Riechert, A. Schmid and B. Buhler, *Biotechnol. Bioeng.*, 2013, **110**, 1282–1292.

167 R. Gudiminchi, C. Randall, D. Opperman, O. Olaofe, S. L. Harrison, J. Albertyn and M. Smit, *Appl. Microbiol. Biotechnol.*, 2012, **96**, 1507–1516.

168 H. Schewe, D. Holtmann and J. Schrader, *Appl. Microbiol. Biotechnol.*, 2009, **83**, 849–857.

169 H. Schewe, B.-A. Kaup and J. Schrader, *Appl. Microbiol. Biotechnol.*, 2008, **78**, 55–65.

170 M.-A. Mirata, M. Wüst, A. Mosandl and J. Schrader, *J. Agric. Food Chem.*, 2008, **56**, 3287–3296.

171 M. Girhard, K. Machida, M. Itoh, R. D. Schmid, A. Arisawa and V. B. Urlacher, *Microb. Cell Fact.*, 2009, **8**, 12.

172 Y. Watanabe, S. Laschat, M. Budde, O. Affolter, Y. Shimada and V. B. Urlacher, *Tetrahedron*, 2007, **63**, 9413–9422.

173 S. C. Maurer, H. Schulze, R. D. Schmid and V. B. Urlacher, *Adv. Synth. Catal.*, 2003, **345**, 802–810.

174 J. A. Dietrich, Y. Yoshikuni, K. J. Fisher, F. X. Woolard, D. Ockey, D. J. McPhee, N. S. Renninger, M. C. Y. Chang, D. Baker and J. D. Keasling, *ACS Chem. Biol.*, 2009, **4**, 261–267.

175 D. K. Ro, E. M. Paradise, M. Ouellet, K. J. Fisher, K. L. Newman, J. M. Ndungu, K. A. Ho, R. A. Eachus, T. S. Ham, J. Kirby, M. C. Y. Chang, S. T. Withers, Y. Shiba, R. Sarpong and J. D. Keasling, *Nature*, 2006, **440**, 940–943.

176 P. r. Tufvesson, J. Lima-Ramos, M. Nordblad and J. M. Woodley, *Org. Process Res. Dev.*, 2010, **15**, 266–274.

177 W. H. Lu, J. E. Ness, W. C. Xie, X. Y. Zhang, J. Minshull and R. A. Gross, *J. Am. Chem. Soc.*, 2010, **132**, 15451–15455.

178 S. Zibek, S. Huf, W. Wagner, T. Hirth and S. Rupp, *Chem. Ing. Tech.*, 2009, **81**, 1797–1808.

179 W. H. Eschenfeldt, Y. Y. Zhang, H. Samaha, L. Stols, L. D. Eirich, C. R. Wilson and M. I. Donnelly, *Appl. Environ. Microbiol.*, 2003, **69**, 5992–5999.

180 S. C. Liu, C. Li, X. C. Fang and Z. A. Cao, *Enzyme Microb. Technol.*, 2004, **34**, 73–77.

181 N. Kawakami, O. Shoji and Y. Watanabe, *Angew. Chem., Int. Ed.*, 2011, **50**, 5315–5318.

182 T. Fujishiro, O. Shoji, N. Kawakami, T. Watanabe, H. Sugimoto, Y. Shiro and Y. Watanabe, *Chem. – Asian J.*, 2012, **7**, 2286–2293.

183 A. Rentmeister, T. R. Brown, C. D. Snow, M. N. Carbone and F. H. Arnold, *ChemCatChem*, 2011, **3**, 1065–1071.

184 C. A. Tracewell and F. H. Arnold, *Curr. Opin. Chem. Biol.*, 2009, **13**, 3–9.

185 J. C. Lewis and F. H. Arnold, *Chimia*, 2009, **63**, 309–312.

186 P. Meinholt, M. W. Peters, A. Hartwick, A. R. Hernandez and F. H. Arnold, *Adv. Synth. Catal.*, 2006, **348**, 763–772.

187 M. W. Peters, P. Meinholt, A. Glieder and F. H. Arnold, *J. Am. Chem. Soc.*, 2003, **125**, 13442–13450.

188 P. C. Cirino and F. H. Arnold, *Angew. Chem., Int. Ed.*, 2003, **42**, 3299–3301.

189 A. Glieder, E. T. Farinas and F. H. Arnold, *Nat. Biotechnol.*, 2002, **20**, 1135–1139.

190 D. F. Munzer, H. Griengl, A. Mountzi, R. Saf, T. Terzani and A. de Raadt, *Eur. J. Org. Chem.*, 2005, 793–796.

191 A. de Raadt and H. Griengl, *Curr. Opin. Biotechnol.*, 2002, **13**, 537–542.

192 A. de Raadt, B. Fetz, H. Griengl, M. F. Klingler, B. Krenn, K. Mereiter, D. F. Munzer, P. Plachota, H. Weber and R. Saf, *Tetrahedron*, 2001, **57**, 8151–8157.

193 G. Braunegg, A. de Raadt, S. Feichtenhofer, H. Griengl, I. Kopper, A. Lehmann and H. J. Weber, *Angew. Chem., Int. Ed.*, 1999, **38**, 2763–2766.

194 E. Weber, A. Seifert, M. Antonovici, C. Geinitz, J. Pleiss and V. B. Urlacher, *Chem. Commun.*, 2011, **47**, 944–946.

195 R. Agudo, G.-D. Roiban and M. T. Reetz, *ChemBioChem*, 2012, **13**, 1465–1473.

196 A. Siriphongphaew, P. Pisnupong, J. Wongkongkatep, P. Inprakhon, A. Vangnai, K. Honda, H. Ohtake, J. Kato, J. Ogawa, S. Shimizu, V. Urlacher, R. Schmid and T. Pongtharangkul, *Appl. Microbiol. Biotechnol.*, 2012, **95**, 357–367.

197 F. van Rantwijk and R. A. Sheldon, *Curr. Opin. Biotechnol.*, 2000, **11**, 554–564.

198 M. Hofrichter and R. Ullrich, *Curr. Opin. Chem. Biol.*, 2014, **19**, 116–125.

199 M. Pešić, C. López, G. Álvaro and J. López-Santín, *J. Mol. Catal. B: Enzym.*, 2012, **84**, 144–151.

200 C. Li, L. Wang, Y. Jiang, M. Hu, S. Li and Q. Zhai, *Appl. Biochem. Biotechnol.*, 2011, **165**, 1691–1707.

201 T. Krieg, S. Huttmann, K.-M. Mangold, J. Schrader and D. Holtmann, *Green Chem.*, 2011, **13**, 2686–2689.

202 S. Aguilera, R. Vazquez-Duhalt, C. Covarrubias, G. Pecchi and J. B. Alderete, *J. Mol. Catal. B: Enzym.*, 2011, **70**, 81–87.

203 V. Yazbik and M. Ansorge-Schumacher, *Process Biochem.*, 2010, **45**, 279–283.

204 G. Díaz-Díaz, M. C. Blanco-López, M. J. Lobo-Castañón, A. J. Miranda-Ordieres and P. Tuñón-Blanco, *J. Mol. Catal. B: Enzym.*, 2010, **66**, 332–336.

205 W. Wang, Y. Xu, D. I. C. Wang and Z. Li, *J. Am. Chem. Soc.*, 2009, **131**, 12892–12893.



206 C. Roberge, D. Amos, D. Pollard and P. Devine, *J. Mol. Catal. B: Enzym.*, 2009, **56**, 41–45.

207 R. Renirie, C. Pierlot, R. Wever and J. M. Aubry, *J. Mol. Catal. B: Enzym.*, 2009, **56**, 259–264.

208 D. I. Perez, F. van Rantwijk and R. A. Sheldon, *Adv. Synth. Catal.*, 2009, **351**, 2133–2139.

209 H. M. de Hoog, M. Nallani, J. Cornelissen, A. E. Rowan, R. J. M. Nolte and I. Arends, *Org. Biomol. Chem.*, 2009, **7**, 4604–4610.

210 B.-A. Kaup, K. Ehrich, M. Pescheck and J. Schrader, *Biotechnol. Bioeng.*, 2008, **99**, 491–498.

211 D. Jung, C. Streb and M. Hartmann, *Microporous Mesoporous Mater.*, 2008, **113**, 523–529.

212 C. E. Grey, F. Rundbäck and P. Adlercreutz, *J. Biotechnol.*, 2008, **135**, 196–201.

213 S. Aguila, R. Vazquez-Duhalt, R. Tinoco, M. Rivera, G. Pecchi and J. B. Alderete, *Green Chem.*, 2008, **10**, 647–653.

214 B. A. Kaup, U. Piantini, M. Wust and J. Schrader, *Appl. Microbiol. Biotechnol.*, 2007, **73**, 1087–1096.

215 C. E. Grey, M. Hedström and P. Adlercreutz, *ChemBioChem*, 2007, **8**, 1055–1062.

216 J.-B. Park and D. S. Clark, *Biotechnol. Bioeng.*, 2006, **94**, 189–192.

217 X. Yi, M. Mroczko, K. M. Manoj, X. Wang and L. P. Hager, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 12412–12417.

218 E. Kiljunen and L. T. Kanerva, *Tetrahedron: Asymmetry*, 1999, **10**, 3529–3535.

219 S. Hu and L. P. Hager, *J. Am. Chem. Soc.*, 1999, **121**, 872–873.

220 L. P. Hager, F. J. Lakner and A. Basavapatruni, *J. Mol. Catal. B: Enzym.*, 1998, **5**, 95–101.

221 S. Aoun and M. Baboulene, *J. Mol. Catal. B: Enzym.*, 1998, **4**, 101–109.

222 F. J. Lakner, K. P. Cain and L. P. Hager, *J. Am. Chem. Soc.*, 1997, **119**, 443–444.

223 F. J. Lakner and L. P. Hager, *J. Org. Chem.*, 1996, **61**, 3923–3925.

224 A. Zaks and D. R. Dodds, *J. Am. Chem. Soc.*, 1995, **117**, 10419–10424.

225 E. J. Allain, L. P. Hager, L. Deng and E. N. Jacobsen, *J. Am. Chem. Soc.*, 1993, **115**, 4415–4416.

226 J. H. Dawson and M. Sono, *J. Am. Chem. Soc.*, 1987, **87**, 1255–1276.

227 J. Geiger, D. J. Daliots, S. L. Neidleman, T. D. Lee and J. Wadsworth, *Biochem. Biophys. Res. Commun.*, 1983, **114**, 1104–1108.

228 E. Churakova, M. Kluge, R. Ullrich, I. Arends, M. Hofrichter and F. Hollmann, *Angew. Chem., Int. Ed.*, 2011, **50**, 10716–10719.

229 X. Wang, S. Peter, R. Ullrich, M. Hofrichter and J. T. Groves, *Angew. Chem., Int. Ed.*, 2013, **52**, 9238–9241.

230 K. Piontek, E. Strittmatter, R. Ullrich, G. Gröbe, M. J. Pecyna, M. Kluge, K. Scheibner, M. Hofrichter and D. A. Plattner, *J. Biol. Chem.*, 2013, DOI: 10.1074/jbc.M113.514521.

231 M. Kluge, R. Ullrich, K. Scheibner and M. Hofrichter, *Green Chem.*, 2012, **14**, 440–446.

232 S. Peter, M. Kinne, X. S. Wang, R. Ullrich, G. Kayser, J. T. Groves and M. Hofrichter, *FEBS J.*, 2011, **278**, 3667–3675.

233 A. Gutierrez, E. D. Babot, R. Ullrich, M. Hofrichter, A. T. Martinez and J. C. del Rio, *Arch. Biochem. Biophys.*, 2011, **514**, 33–43.

234 K. Barková, M. Kinne, R. Ullrich, L. Hennig, A. Fuchs and M. Hofrichter, *Tetrahedron*, 2011, **67**, 4874–4878.

235 M. M. Vdovenko, R. Ullrich, M. Hofrichter and I. Y. Sakharov, *Appl. Biochem. Microbiol.*, 2010, **46**, 65–68.

236 K. Piontek, R. Ullrich, C. Liers, K. Diederichs, D. A. Plattner and M. Hofrichter, *Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.*, 2010, **66**, 693–698.

237 M. Kinne, C. Zeisig, R. Ullrich, G. Kayser, K. E. Hammel and M. Hofrichter, *Biochem. Biophys. Res. Commun.*, 2010, **397**, 18–21.

238 E. Aranda, R. Ullrich and M. Hofrichter, *Biodegradation*, 2010, **21**, 267–281.

239 R. Ullrich, C. Liers, S. Schimpke and M. Hofrichter, *Biotechnol. J.*, 2009, **4**, 1619–1626.

240 M. J. Pecyna, R. Ullrich, B. Bittner, A. Clemens, K. Scheibner, R. Schubert and M. Hofrichter, *Appl. Microbiol. Biotechnol.*, 2009, **84**, 885–897.

241 M. Kinne, M. Poraj-Kobielska, S. A. Ralph, R. Ullrich, M. Hofrichter and K. E. Hammel, *J. Biol. Chem.*, 2009, **284**, 29343–29349.

242 M. Kinne, M. Poraj-Kobielska, E. Aranda, R. Ullrich, K. E. Hammel, K. Scheibner and M. Hofrichter, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 3085–3087.

243 M. Kinne, R. Ullrich, K. E. Hammel, K. Scheibner and M. Hofrichter, *Tetrahedron Lett.*, 2008, **49**, 5950–5953.

244 R. Ullrich and M. Hofrichter, *Cell. Mol. Life Sci.*, 2007, **64**, 271–293.

245 A. But, J. Le Nôtre, E. L. Scott, R. Wever and J. P. M. Sanders, *ChemSusChem*, 2012, **5**, 1199–1202.

246 M. Schrewe, M. K. Julsing, B. Bühler and A. Schmid, *Chem. Soc. Rev.*, 2013, **42**, 6346–6377.

247 L. M. Blank, G. Ionidis, B. E. Ebert, B. Bühler and A. Schmid, *FEBS J.*, 2008, **275**, 5173–5190.

248 D. Meyer, B. Witholt and A. Schmid, *Appl. Environ. Microbiol.*, 2005, **71**, 6624–6632.

249 M. J. Fink, F. Rudroff and M. D. Mihovilovic, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 6135–6138.

250 M. D. Mihovilovic, P. Kapitan and P. Kapitanova, *ChemSusChem*, 2008, **1**, 143–148.

251 E. Churakova, B. Tomaszewski, K. Buehler, A. Schmid, I. W. C. E. Arends and F. Hollmann, *Top. Catal.*, 2014, **57**, 385–391.

252 D. E. Torres Pazmiño, A. Riebel, J. d. Lange, F. Rudroff, M. D. Mihovilovic and M. W. Fraaije, *ChemBioChem*, 2009, **10**, 2595–2598.

253 D. E. Torres Pazmiño, R. Snajdrova, B.-J. Baas, M. Ghobrial, M. D. Mihovilovic and M. W. Fraaije, *Angew. Chem., Int. Ed.*, 2008, **47**, 2307–2310.

254 A. Rioz-Martínez, G. de Gonzalo, T. P. D. E. M. W. Fraaije and V. Gotor, *Eur. J. Org. Chem.*, 2009, 2526–2532.

255 E. Beneventi, G. Ottolina, G. Carrea, W. Panzeri, G. Fronza and P. C. K. Lau, *J. Mol. Catal. B: Enzym.*, 2009, **58**, 164–168.

256 C. Rodriguez, G. de Gonzalo, M. W. Fraaije and V. Gotor, *Tetrahedron: Asymmetry*, 2007, **18**, 1338–1344.

257 M. Mifsud, S. Gargiulo, S. Iborra, I. W. C. E. Arends, F. Hollmann and A. Corma, *Nat. Commun.*, 2014, **5**, DOI: 10.1038/ncomms4145.

258 F. Hollmann, I. W. C. E. Arends and K. Buehler, *ChemCatChem*, 2010, **2**, 762–782.

259 M. P. Mayhew, V. Reipa, M. J. Holden and V. L. Vilker, *Biotechnol. Prog.*, 2000, **16**, 610–616.

260 D. Lim, Y. H. Kim, J. C. Joo and Y. J. Yoo, *Enzyme Microb. Technol.*, 2010, **47**, 313–321.

261 A. Vaze, M. Parizo and J. F. Rusling, *Langmuir*, 2004, **20**, 10943–10948.

262 B. Munge, C. Estavillo, J. B. Schenkman and J. F. Rusling, *ChemBioChem*, 2003, **4**, 82–89.

263 V. Reipa, M. P. Mayhew and V. L. Vilker, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, **94**, 13554–13558.

264 K. M. Faulkner, M. S. Shet, C. W. Fisher and R. W. Estabrook, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 7705–7709.

265 L. Zhao, G. Güven, Y. Li and U. Schwaneberg, *Appl. Microbiol. Biotechnol.*, 2011, **91**, 989–999.

266 U. Schwaneberg, D. Appel, J. Schmitt and R. D. Schmid, *J. Biotechnol.*, 2000, **84**, 249–257.

267 A. K. Udit, F. H. Arnold and H. B. Gray, *J. Inorg. Biochem.*, 2004, **98**, 1547–1550.

268 N.-H. Tran, N. Huynh, T. Bui, Y. Nguyen, P. Huynh, M. E. Cooper and L. E. Cheruzel, *Chem. Commun.*, 2011, **47**, 11936–11938.

269 F. E. Zilly, A. Taglieber, F. Schulz, F. Hollmann and M. T. Reetz, *Chem. Commun.*, 2009, 7152–7154.

270 F. W. Ströhle, S. Z. Čekic, A. O. Magnusson, U. Schwaneberg, D. Roccatano, J. Schrader and D. Holtmann, *J. Mol. Catal. B: Enzym.*, 2013, **88**, 47–51.

271 C. Ley, H. Schewe, F. W. Ströhle, A. J. Ruff, U. Schwaneberg, J. Schrader and D. Holtmann, *J. Mol. Catal. B: Enzym.*, 2013, **92**, 71–78.

272 D. Holtmann, K.-M. Mangold and J. Schrader, *Biotechnol. Lett.*, 2009, **31**, 765–770.

273 S. Z. Čekic, D. Holtmann, G. Güven, K.-M. Mangold, U. Schwaneberg and J. Schrader, *Electrochem. Commun.*, 2010, **12**, 1547–1550.

274 V. Massey, *J. Biol. Chem.*, 1994, **269**, 22459–22462.

275 B. Valderrama, M. Ayala and R. Vazquez-Duhalt, *Chem. Biol.*, 2002, **9**, 555–565.

276 R. Narayanan, G. Y. Zhu and P. Wang, *J. Biotechnol.*, 2007, **128**, 86–92.

277 A. Borole, S. Dai, C. L. Cheng, M. Rodriguez and B. H. Davison, *Appl. Biochem. Biotechnol.*, 2004, **113**, 273–285.

278 F. van de Velde, N. D. Lourenco, M. Bakker, F. van Rantwijk and R. A. Sheldon, *Biotechnol. Bioeng.*, 2000, **69**, 286–291.



279 A. D. Ryabov, Y. N. Firsova, V. N. Goral, E. S. Ryabova, A. N. Shevelkova, L. L. Troitskaya, T. V. Demeschik and V. I. Sokolov, *Chem. – Eur. J.*, 1998, **4**, 806–813.

280 K. Lee and S.-H. Moon, *J. Biotechnol.*, 2003, **102**, 261–268.

281 C. E. La Rotta, E. D'Elia and E. P. S. Bon, *Electron. J. Biotechnol.*, 2007, **10**, 24–37.

282 C. Kohlmann, L. Greiner, W. Leitner, C. Wandrey and S. Lütz, *Chem. – Eur. J.*, 2009, **15**, 11692–11700.

283 C. Kohlmann and S. Lütz, *Eng. Life Sci.*, 2006, **6**, 170–174.

284 L. Getrey, T. Krieg, F. Hollmann, J. Schrader and D. Holtmann, *Green Chem.*, 2014, **16**, 1104–1108.

285 S. K. Karmee, C. Roosen, C. Kohlmann, S. Lütz, L. Greiner and W. Leitner, *Green Chem.*, 2009, **11**, 1052–1055.

286 E. Churakova, I. W. C. E. Arends and F. Hollmann, *ChemCatChem*, 2013, **5**, 565–568.

287 D. I. Perez, M. Mifsud Grau, I. W. C. E. Arends and F. Hollmann, *Chem. Commun.*, 2009, 6848–6850.

288 P. Anastas and N. Eghbali, *Chem. Soc. Rev.*, 2010, **39**, 301–312.

289 R. A. Sheldon, *Chem. Commun.*, 2008, 3352–3365.

290 Y. Ni, D. Holtmann and F. Hollmann, *ChemCatChem*, 2014, **6**, 930–943.

291 M. Eissen, *Chem. Educ. Res. Pract.*, 2012, **13**, 103–111.

292 E. Heinzle, A. Biwer, M. Eissen and M. A. Kholid, *Chem. Ing. Tech.*, 2006, **78**, 301–305.

293 M. Eissen and J. O. Metzger, *Chem. – Eur. J.*, 2002, **8**, 3580–3585.

294 F. G. Calvo-Flores, *ChemSusChem*, 2009, **2**, 905–919.

295 M. Ribeiro and A. Machado, *Green Chem. Lett. Rev.*, 2013, **6**, 1–18.

296 D. Ravelli, S. Protti, P. Neri, M. Fagnoni and A. Albini, *Green Chem.*, 2011, **13**, 1876–1884.

297 B. Buhler and A. Schmid, *J. Biotechnol.*, 2004, **113**, 183–210.

298 B. Buhler, I. Bollhalder, B. Hauer, B. Witholt and A. Schmid, *Biotechnol. Bioeng.*, 2003, **82**, 833–842.

299 B. Buhler, I. Bollhalder, B. Hauer, B. Witholt and A. Schmid, *Biotechnol. Bioeng.*, 2003, **81**, 683–694.

300 B. Buhler, B. Witholt, B. Hauer and A. Schmid, *Appl. Environ. Microbiol.*, 2002, **68**, 560–568.

301 R. Gandolfi, K. Cavenago, R. Gualandris, J. V. Sinisterra Gago and F. Molinari, *Process Biochem.*, 2004, **39**, 749–753.

302 R. Villa, A. Romano, R. Gandolfi, J. V. Sinisterra Gago and F. Molinari, *Tetrahedron Lett.*, 2002, **43**, 6059–6061.

303 Y. Ni, P.-L. Hagedoorn, J.-H. Xu, I. W. C. E. Arends and F. Hollmann, *Chem. Commun.*, 2012, **48**, 12056–12058.

304 P. Könst, S. Kara, S. Kochius, D. Holtmann, I. W. C. E. Arends, R. Ludwig and F. Hollmann, *ChemCatChem*, 2013, **5**, 3027–3032.

305 S. Kara, D. Spickermann, J. H. Schrittawieser, A. Weckbecker, C. Leggewie, I. W. C. E. Arends and F. Hollmann, *ACS Catal.*, 2013, **3**, 2436–2439.

306 A. Diaz-Rodríguez, J. Iglesias-Fernández, C. Rovira and V. Gotor-Fernández, *ChemCatChem*, 2013, **6**, 977–980.

307 P. G. Jessop, *Green Chem.*, 2011, **13**, 1391–1398.

308 C. Capello, U. Fischer and K. Hungerbuhler, *Green Chem.*, 2007, **9**, 927–934.

309 R. A. Sheldon, *Green Chem.*, 2005, **7**, 267–278.

310 J. Schrittawieser, F. Coccia, S. Kara, B. Grischek, W. Kroutil, N. d'Alessandro and F. Hollmann, *Green Chem.*, 2013, **15**, 3318–3331.

311 J. H. Schrittawieser, J. Sattler, V. Resch, F. G. Mutti and W. Kroutil, *Curr. Opin. Chem. Biol.*, 2011, **15**, 249–256.

312 E. Ricca, B. Brucher and J. H. Schrittawieser, *Adv. Synth. Catal.*, 2011, **353**, 2239–2262.

313 M. Schrewe, N. Ladkau, B. Bühler and A. Schmid, *Adv. Synth. Catal.*, 2013, **355**, 1693–1697.

314 M. Schrewe, A. O. Magnusson, C. Willrodt, B. Bühler and A. Schmid, *Adv. Synth. Catal.*, 2011, **353**, 3485–3495.

